CLL Sector Heats Up, AbbVie/Roche Upbeat About First-Line Venetoclax Combo
Executive Summary
Positive top-line data on use of an AbbVie/Genentech's venetoclax combination as a first-line chronic lymphocytic leukemia therapy heralds stiffer competition in the therapeutic sector in the years to come.
You may also be interested in...
Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma
Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.
Verastem’s Copiktra Gets Early Approval To Challenge Zydelig, Venclexta In Third-Line CLL
Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.